BioCentury
ARTICLE | Company News

BioTime, Summit Pharmaceuticals deal

January 3, 2005 8:00 AM UTC

The companies partnered to develop BTX's Hextend and PentaLyte plasma extenders in Japan to treat hypovolemia (low blood volume). Summit will reimburse $900,000 of BTX's development costs. Also, BTX ...